David Liebowitz

novel vaccine development company. He was previously the Chief Scientific and Medical Officer for Vivaldi Biosciences, an influenza vaccine and therapeutics biotechnology company. Prior to that, he was the Executive Vice President of Research and Development at Galileo Pharmaceuticals, and he also served as co-CEO of Galileo for a period of time. Prior to joining Galileo, Dr. Liebowitz was at Amgen, where he was the Director of Research responsible for all oncology and vascular biology drug discovery and development programs at their Washington research site. He also managed external development collaborations and licensing activities. Dr. Liebowitz joined Amgen through their acquisition of Immunex, where he held several senior positions in clinical and preclinical development. Prior to joining Immunex, he was an Associate Investigator in the Abramson Cancer Institute at the University of Pennsylvania, where he was Director of their immunotherapy and cellular therapy programs targeting cancer and chronic viral diseases. Dr. Liebowitz was an early recipient of a grant from the Bill and Melinda Gates foundation. He began his academic career as an Assistant Professor of Medicine and Virology at the University of Chicago, and was the Director of the Bone Marrow Transplantation Program. Dr. Liebowitz has B.S. and M.S. degrees in Biology from Emory University, an M.D. with honors and a Ph.D. in Molecular Genetics and Cell Biology, both from the University of Chicago.